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following CATH and PCI, including settings in which use of contrast-sparing techniques
are standard of practice.
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Background: There is only limited and conflicting information about the impact of
pre-operative chronic kidney disease (CKD) on outcome after transcatheter aortic valve
implantation (TAVI). We sought to evaluate the impact of pre-operative CKD on clinical
outcome after TAVI, with either balloon- or self-expandable prosthesis, using transfemo-
ral or alternative access, in high risk patients with severe aortic stenosis.
Methods: We retrospectively analyzed pooled data from 4 centers’ prospective TAVI
databases (942 patients). VARC endpoint definitions were used. Patients were subdivided
into 4 categories of eGFR to examine the effect of: no ( 90 ml/min/1.73 m2), mild (61
to 90 ml/min/1.73 m2), moderate (31 – 60 ml/min/1.73 m2) and severe ( 30 ml/min/1.73
m2) CKD. To assess the effect of renal function on short- and long-term outcome,
univariable and multivariable logistic regressions were used; no-CKD category was the
reference category.
Results: No CKD was found in 109 patients (11.6%); 330 (35 %) had mild, 400 (42.4
%) moderate and 103 (11%) severe CKD. Baseline and procedural characteristics were
similar among all groups except for the Logistic EuroSCORE, incidence of severe left
ventricular dysfunction, anemia, and a transapical approach, which was higher when the
CKD was more severe. Major stroke (severe CKD: 4.9 %, moderate: 2.8 %, mild: 1.2 %,
no: 1.8 %, p0.05), life-threatening bleeding (severe CKD: 24.3%, moderate 14.8 %,
mild: 11.2 %, no: 8.3 %, p0.001), all-cause 30-day mortality (severe CKD 9.7%,
moderate 8.5%, mild 6.7%, no 1.7%, p0.02) and one-year mortality differed signifi-
cantly across CKD groups. By multivariate analysis, severe CKD (HR 4.21, 95 % CI
1.67-10.66) was an independant predictor of one-year mortality.
Conclusions: Patients with CKD who undergo TAVI have a higher risk profile and a
worse 30-day and one-year outcome. Severe CKD at baseline is an independent predictor
of 1-year mortality after TAVI.
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Background: Diagnosis of acute kidney injury (AKI) relies on a late marker, namely
serum creatinine (SCr). Several biomarkers are considered for an early and sensitive
detection of contrast-induced nephropathy (CIN). In particular, urinary Neutrophil
Gelatinase-Associated Lipocalin (uNGAL) has been used for early detection of AKI in the
emergency department, after cardiopulmonary bypass or following contrast medium
(CM) exposition. Our study was conducted to assess the value of uNGAL as an early
detector of CIN in patients undergoing percutaneous coronary procedures (PCP) and
whether or not uNGAL correlates with the volume of CM.
Methods: We enrolled 244 consecutive patients undergoing PCP with Iomeprolum at our
institution. CIN was defined as a25% increase in SCr from baseline when measured 2-4
days after PCP. uNGAL was measured at its peak (4-6 hours after PCP) with the Abbott
ARCHITECT assay.
Results: Among the patients (median[iqr] age 66.6[59.5-74.7] years, 70% male),
149(61%) underwent a diagnostic PCP and 95(39%) underwent a therapeutic PCP with a
median CM volume of 123[88-168] ml. 25(10%) patients developed CIN after PCP. We
found neither a significant difference in uNGAL levels between patients with and without
CIN (p0.20), nor a significant correlation between the CM volume versus uNGAL
levels (r-0.11) (Fig. 1).
Conclusions: In a large cohort of patients at low-risk for contrast-induced nephropathy,
urinary NGAL measured 4 to 6 hours after PCP was not useful in predicting the
development of contrast-induced nephropathy and did not correlate with the volume of
contrast medium used during the procedure.
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Background: Contrast-induced acute kidney injury (CI-AKI) continues to be an
important complication of contrast administration. We’ve recently discovered the utility
of substituted cyclodextrins (SCD) for mitigating the renal toxicity of several classes of
nephrotoxic agents including antibiotics, anticancer agents and contrast agents (CA). This
discovery is the basis for the development of Veropaque, a new contrast agent containing
iohexol and a SCD. Here we report on preclinical animal studies using several CAs and
SCDs.
Methods: Formulations containing iopamidol, iodixanol and iohexol were prepared
w/wo various amounts of sulfobutylether--cyclodextrin (SBECD) or 2-hydroxypropyl-
-cyclodextrin (HPCD). The formulations were dosed iv at 1.5 g Iodine/kg to renally
compromised (RC) mice and rats. Plasma samples were taken for creatinine analysis, and
kidney pathology was evaluated at 24 or 48h. A 14-day survival study in RC rats was also
conducted with 2.5g I/mL iv doses of iohexol or iohexol	SBECD (Veropaque). The
iohexol and Veropaque formulations were also rapidly injected into the left main coronary
artery of anesthetized instrumented dogs. ECG and hemodynamics were monitored.
Results: Small amounts of SCD added to CA formulations dramatically reduced the
kidney pathology in both rats and mice at 24 and 48h and preserved kidney function as
measured by plasma creatinine. The nephroprotection was observed for both SCDs and all
three CAs and was dose dependent on the SCD from CA:SCD mole ratios of 1:0.0125 to
1:0.05. The SCD also reduced mortality in the 14-day study (8/8 control, 4/8 iohexol, 7/8
Veropaque survived). Intracoronary injections in the dog model revealed no significant
differences between iohexol and Veropaque and no notable effects on most measured
cardiovascular parameters other than transient changes in LV contractility and QTc
interval as previously described in the literature.
Conclusions: SCDs are nephroprotective against CI-AKI pathology, functional changes,
and mortality in rodent models without altering the expected cardiac hemodynamic and
electrophysiologic effects of the CAs. Further development of Veropaque is warranted and
underway.
TCT-139
Prognosis and Incidence of Acute kidney Injury According to the Valve
Academic Research Consortium after Transcatheter Aortic Valve
Implantation.
marc bedossa1, vincent auffret1, dominique boulmier1, erwan donal1,
jean philippe Verhoye2, gienvitto ruggieri2, herve le breton1
1department of cardiology, Rennes, France, 2department of cardiac surgery,
Rennes, France
Background: Few data are currently available about the characteristics and procedural
features associated with Acute kidney Injury (AKI) after Transcatheter Aortic Valve
Implantation (TAVI) using the new recommended Valve Academic Research Consortium
(VARC) definition.
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